In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

Merck & Co has announced the US launch of a mobile app designed to help and enhance communications between diabetes patients and educators. US-based Merck said the app known as map4health was ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

Merck reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in ...

It's worth noting that the agreement has been forged a few months after Merck suffered a setback in its attempt to secure FDA approval for a potentially first-in-class drug for chronic cough ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company.

Accra [Ghana]/ Mumbai (Maharashtra) [India], November 14: Merck Foundation, the philanthropic arm of Merck KGaA Germany, marks 'World Diabetes Day 2024' together with Africa's First Ladies, Ministries ...

Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has ...

Adjusted for one-time items that included a 79-cent-a-share charge related to the business development deals, EPS came to $1.57, ahead of the FactSet consensus of $1.48. Sales rose 4% to $16.657 ...